摘要
目的:探究重组人干扰素α-1b对反复呼吸道感染患儿免疫及炎症状态的影响。方法:选取166例反复呼吸道感染患儿作为研究对象,随机分为研究组和对照组各83例,其中对照组采用常规治疗方法进行治疗,研究组在其基础上采用重组人干扰素α-1b进行治疗,一个疗程后,比较两组患者治疗效果、治疗前后免疫球蛋白指标水平及T淋巴细胞群检查指标水平。结果:研究组治疗总有效率(86.75%)显著高于对照组(61.45%),两组数据的差异具有统计学意义(P<0.001,x2=13.841)。治疗前,两组患者IgA、IgM、IgG的差异无统计学意义(P>0.05);治疗后,研究组IgM水平高于对照组(P=0.092,t=1.332),IgA、IgG水平显著高于对照组,差异具有统计学意义(P<0.001,t=93.047;P<0.001,t=8.037)。治疗前,两组患者CD4+、CD3+、CD4+/CD8+三项指标水平无明显差异(P>0.05);治疗后,两组患者三项指标水平均明显升高,且研究组三项指标水平均显著高于对照组,差异具有统计学意义(P<0.001,t=15.515;P<0.001,t=7.346;P<0.001,t=5.462)。通过6个月的随访,研究组复发率(50.60%)明显低于对照组(69.88%),两组数据的差异具有统计学意义(P=0.011,t=6.439)。研究组患者发作次数明显少于对照组,病程显著短于对照组,两组数据的差异具有统计学意义(P<0.001,t=6.386;P<0.001,t=6.306)。研究组发生不良反应17例,占20.48%,对照组发生不良反应24例,占28.91%,两组数据的差异无统计学意义(x2=1.587,P=0.208)。结论:重组人干扰素α-1b对反复呼吸道感染患儿治疗效果优越,可有效控制患儿病情,改善机体免疫功能,值得临床推广应用。
Objective: To explore the effects of recombinant human interferon alpha-1 b on immunity and inflammation status of children with recurrent respiratory tract infection. Methods: 166 children with recurrent respiratory tract infections were selected as subjects,which were randomly divided into the study group and the control group with 83 cases in each group. The control group was treated with the routine therapy while the study group was treated with recombinant human interferon alpha-1 b on the basis of the routine treatment. After one course of treatment, the therapeutic effect, levels of immunoglobulin indexes and T lymphocyte population indexes of the two groups were compared. Results: The total effective rate of the study group is 86.75%, which is significantly higher than that of the control group(61.45%). The differences of the data between the two groups have statistical significance(P<0.001, x2 = 13.841). Before treatment, the differences have no statistical significance in the levels of IgA, IgM and IgG between the two groups(P>0.05). After treatment, the level of IgM in the study group is higher than that in the control group(P = 0.092, t = 1.332). the levels of IgA and IgG are significantly higher than those in the control group(P<0.001, t = 93.047;P<0.001, t = 8.037). Before treatment, there are no significant differences in the levels of CD4+, CD3+, CD4+/CD8+ between the study group and the control group(P>0.05). After two weeks of treatment, the levels of above indexes in each group have significantly increased, and the levels of three indexes in the study group are significantly higher than those in the control group(P<0.001, t = 15.515;P<0.001, t=7.346;P<0.001, t = 5.462). After 6 months of follow-up research, the recurrence rate of the study group is 50.60%, which is significantly lower than that of the control group(69.88%). There are significant differences between the two groups(P = 0.011, t = 6.439). The number of attacks in the study group is significantly fewer than that in the control group, and the course of the disease is significantly shorter than that of the control group. The data between the two groups have statistical significance(P<0.001, t = 6.386;P<0.001, t = 6.306). 17 cases(20.48%) of adverse reactions were found in the study group and 24 cases(28.91%) in the control group. The differences of the data between the two groups have statistical significance(x2 = 1.587, P = 0.208). Conclusion: Recombinant human interferon alpha-1 b has superior therapeutic effect on children with recurrent respiratory tract infection. It can effectively control the conditions of children and improve the immune function of the body, and is worthy of clinical application.
作者
孙玉
侯娥艳
Sun Yü;Hou E'yan(Chengwu People's Hospital,Heze 274200,China)
出处
《中国药事》
CAS
2020年第5期608-613,共6页
Chinese Pharmaceutical Affairs
关键词
重组人干扰素Α-1B
反复呼吸道感染
免疫
炎症状态
recombinant human interferon alpha-1b
recurrent respiratory tract infection
immunity
inflammation status
